Editas Medicine, INC. (EDIT) — 10-Q Filings
All 10-Q filings from Editas Medicine, INC.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
Editas Narrows Losses, Boosts Revenue Amid Restructuring
— Nov 10, 2025 Risk: high
Editas Medicine, Inc. (EDIT) reported a net loss of $25.1 million for the three months ended September 30, 2025, a significant improvement from the $62.1 millio -
Editas Medicine's Restricted Cash Holds Steady at $3,877
— Aug 12, 2025 Risk: medium
Editas Medicine, Inc. reported restricted cash of $3,877 as of June 30, 2025, which remained unchanged from June 30, 2024. The filing indicates no significant c -
Editas Medicine Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
Editas Medicine, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in Cambridge, MA, is involved in biological products. -
Editas Medicine Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Editas Medicine, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company's financia
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX